Moderna stock crashes as leaked melanoma data threatens its record August rally - Yahoo Finance
Moderna stock experienced a significant decline following the leak of clinical trial data for its melanoma vaccine. While the leaked results still indicate efficacy, the market reacted negatively due to the stock's previous rapid valuation growth.
Why it matters
The volatility highlights the sensitivity of biotech stocks to clinical trial outcomes and the impact of information leaks on market valuation.
Moderna stock crashes as leaked melanoma data threatens its record August rally Jared Blikre Fri, October 23, 2026 at 4:24 PM GMT+8 2 min read MRNA -1.25% MRK -1.34% Two months ago, Moderna's ( MRNA ) melanoma vaccine handed the stock its best day ever. Now leaked results from the same trial have handed it its biggest intraday drop on record.
The stock fell as much as 26% before closing down more than 17%. That's still its worst day since Aug. 20, the session right after its best day.
Moderna stock fell 3% during premarket trading on Friday.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in